Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Editorial Board590
Editorial Board303
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer257
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor238
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor221
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma216
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea215
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma204
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer179
Unraveling the secrets: Evolution of resistance mediated by membrane proteins150
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome147
Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903]146
Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer144
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance143
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects139
Editorial Board135
Evolution of RND efflux pumps in the development of a successful pathogen133
A novel frameshift mutation in a case of therapy-resistant metastatic pheochromocytoma129
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance129
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer117
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China114
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges100
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae99
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies94
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions90
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis89
Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence88
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation85
IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms80
Corrigendum to “RNF26 regulating tumor immunogenicity of hepatocellular carcinoma by degrading GRP78 and instigating ER stress” [Drug Resist. Updat. 86 (2026) 101375]78
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells77
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma75
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC74
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs73
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs70
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond68
Targeting anoikis resistance as a strategy for cancer therapy67
Editorial Board67
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress65
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds63
Research progress on gene mutations and drug resistance in leukemia63
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica63
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity62
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers61
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights59
Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance58
The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence56
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer56
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma54
Overcoming cancer chemotherapy resistance by the induction of ferroptosis54
Current therapy and drug resistance in metastatic castration-resistant prostate cancer52
Myeloid immune checkpoint blockade overcomes antibiotic resistance in bone infection by enhancing efferocytosis and suppressing MSC PANoptosis52
0.079671144485474